Neonatal Alloimmune Thrombocytopenia (NAIT) Registry


Steering Committee Chair: Dr Steve Cole
Click here for full Steering Committee Details.

What it NAIT?

Special markers (also known as antigens) on the surface of platelets determine a person's platelet blood group.  A baby inherits these markers from its mother and father, so in some cases a mother and baby can have different platelet groups.  In this situation, the mother's immune defense system may perceive the baby's platelets to be "foreign".  When this occurs, she may make antibodies, which can cross the placenta into the baby's blood and damage the baby's platelets, causing a low platelet count.

The effect on the baby depends on how many platelets are damaged. If this is mild then no harm will come to the baby.  If the platelet count is very low this could lead to bleeding, even before the baby is horn, and sometimes this bleeding can have serious consequences.  It is important that specialist care be provided to mothers with a history of NAIT.

Currently there is no consensus regarding the incidence of NAIT in Australia, its optimal management, clinical outcome, or the impact of complications, nor standardisation of laboratory assessments.  Lack of data hampers the design of clinical interventional studies and laboratory testing.

The NAIT Registry recruits patients through treating clinicians at multiple sites across Australia, collects data via a specifically designed web-based data collection form and aims to:

  • Better define the incidence, natural history and clinical outcome of NAIT.
  • Provide information on the range of therapeutic strategies being employed in the treatment of NAIT patients.
  • Explore factors influencing clinical outcomes.
  • Better define optimal management of NAIT patients.
  • Inform and inspire future research, and coordinate future national research.

If you would like more information or are interested in the participating in the NAIT Registry please click here